Xyrem TPP — Settlement Summary

Last Modified on 10/28/2026 6:01 pm EDT

In Re Xyrem Antitrust Litigation – Third-Party Payor Settlement

Summary

This class action lawsuit alleges that Jazz Pharmaceuticals and its co-defendants unlawfully delayed generic competition for Xyrem and allocated the market, causing third-party payors (TPPs) and other purchasers to overpay for brand and generic Xyrem and/or Xywav. New settlements totaling **$195 million** have been reached with Jazz and Hikma, in addition to previously approved settlements totaling $3.4 million with Amneal and Lupin. The Court granted final approval of the settlements on October 27, 2025, and payments are expected to be issued during the fourth quarter of 2026.

Announcements

- **Final Approval Granted (October 27, 2025):** The Court granted final approval of the Jazz and Hikma settlements. A copy of the Final Approval Order and Judgment is available on the Court Documents page of the settlement website.
- **Claims Processing Underway:** The Notice and Claims Administrator is currently reviewing and processing submitted claims and will contact claimants if additional information is needed.
- **Payment Timeline:** Payments are expected to be issued during the **fourth quarter of 2026**.
- **Filing Deadline Has Passed:** The claim form deadline was **October 3, 2025**. The opt-out and objection deadline of July 28, 2025 has also passed.

Settlement Amount

The total settlement fund is **$195 million** from Jazz Pharmaceuticals entities and Hikma Pharmaceuticals entities combined. Additionally, the Court previously approved separate settlements totaling **$3.4 million** with Amneal Pharmaceuticals LLC and Lupin Ltd./Lupin Pharmaceuticals Inc./Lupin Inc. Per-claimant recovery amounts have not been published on the settlement website; individual payments will depend on the number of valid claims filed and the Plan of Allocation.

Class Period

January 1, 2017 through May 16, 2025.

Filing Deadline

The filing deadline has passed. Claim forms were required to be postmarked (if mailed) or received online on or before **October 3, 2025**. The Notice and Claims Administrator is now reviewing submitted claims.

Who Qualifies

You may be included in the settlements if you are an **entity** (e.g., a third-party payor such as a health insurer, self-insured employer, or union health and welfare fund) that paid and/or provided reimbursement for some or all of the purchase price for **brand or generic Xyrem** in any of the following jurisdictions during the class period:

- Alaska, Arizona, Arkansas, California, Connecticut, District of Columbia, Florida, Hawaii, Illinois, Iowa, Kansas,

Maine, Maryland, Massachusetts, Michigan, Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New Mexico, New York, North Carolina, North Dakota, Oregon, Puerto Rico, Rhode Island, South Carolina, South Dakota, Tennessee, Utah, Vermont, West Virginia, and/or Wisconsin.

The full class definition is available in the official Class Action Notice posted on the settlement website.

Who Is Excluded

The full list of excluded parties is set forth in the official Class Action Notice. The settlement website notes that the complete class definition and exclusions are detailed in the Notice. Generally, defendants and their affiliates, government entities, and certain other parties are typically excluded from class action settlements of this type. *FRS staff should consult the Notice on the Court Documents page for the precise exclusion language.*

How to File

Note: The October 3, 2025 claim filing deadline has passed. The information below is retained for reference and audit purposes.

- **Step 1:** Obtain a Claim Form from the settlement website at www.InReXyremAntitrustLitigation.com via the "File a Claim" page.
- **Step 2:** Complete the Claim Form with all required information about your entity's Xyrem purchases and/or reimbursements during the class period (January 1, 2017 – May 16, 2025).
- **Step 3:** Submit the completed Claim Form either:
  - *Online:* Through the settlement website (submission must have been received by October 3, 2025), or
  - *By Mail:* Postmarked no later than October 3, 2025.
- **Step 4:** The Notice and Claims Administrator will review submitted claims and contact claimants if additional information or documentation is needed.
- **Step 5:** If your claim is approved, payments are expected to be distributed during the **fourth quarter of 2026**.

For questions, contact the Notice and Claims Administrator by phone at **877-495-0891** or through the contact form at www.InReXyremAntitrustLitigation.com.

Defendants

- **Jazz Pharmaceuticals, Inc.; Jazz Pharmaceuticals Ireland Limited; Jazz Pharmaceuticals Public Limited Company ("Jazz")** — Alleged to have unlawfully delayed the availability of generic versions of Xyrem and allocated the market.
- **Hikma Pharmaceuticals plc; Hikma Pharmaceuticals USA Inc.; Hikma Labs, Inc.; Eurohealth (USA), Inc. ("Hikma")** — Named as co-defendant in the alleged anticompetitive scheme; settling for a portion of the $195 million combined fund.
- **Amneal Pharmaceuticals LLC ("Amneal")** — Previously settled separately; the Court approved a settlement of $3.4 million (combined with Lupin) prior to the Jazz/Hikma settlements.
- **Lupin Ltd.; Lupin Pharmaceuticals Inc.; Lupin Inc. ("Lupin")** — Previously settled separately alongside Amneal for the $3.4 million combined amount.

All defendants deny any wrongdoing. The lawsuit alleges violations of certain state antitrust and consumer protection laws. No claims are made that Xyrem or Xywav are unsafe.

Case History

- **Class Period Start – January 1, 2017:** Beginning of the period during which plaintiffs allege defendants' anticompetitive conduct caused class members to overpay for Xyrem.

- **Prior to 2025:** The Court previously approved settlements totaling $3.4 million with Amneal and Lupin.
- **Class Period End – May 16, 2025:** End of the eligible class period for the Jazz/Hikma settlements.
- **July 28, 2025:** Deadline for class members to opt out of or object to the Jazz/Hikma settlements.
- **October 3, 2025:** Claim form submission deadline.
- **October 23, 2025:** Final Approval Hearing held in person before the Honorable Richard Seeborg, U.S. District Court, Northern District of California, San Francisco Courthouse, 450 Golden Gate Ave., San Francisco, CA 94102, Courtroom 3, 17th Floor.
- **October 27, 2025:** Court granted final approval of the Jazz and Hikma settlements.
- **Q4 2026 (expected):** Payment distribution to approved claimants anticipated.

Source

www.InReXyremAntitrustLitigation.com

Last Updated

2026-10-28

Reviewer Flags

- **Changes from previous version:**
  - **Payment timeline updated (Q3 2026 → Q4 2026):** The previous article stated payments were expected in the "third quarter of 2026." The current source page explicitly states payments are expected during the "fourth quarter of 2026." This change has been applied in the Summary, Announcements, How to File (Step 5), and Case History sections.
  - **Last Updated date:** Updated from 2025-09-22 to 2026-10-28 per instructions.
  - **Reviewer flag resolved:** The prior version flagged a potential contradiction regarding whether Q3 2026 payments had been issued as of the 2026-09-22 last-updated date. The source page now clarifies the payment window is Q4 2026, resolving that concern.
- **Source pages:** All information in this article was drawn from the single monitored page: the Xyrem TPP Homepage at www.InReXyremAntitrustLitigation.com.
- **Ongoing flags (unchanged from prior version):**
  - **Per-claimant recovery:** No per-claimant recovery estimate is published on the settlement website. Reviewer should check whether a Plan of Allocation document on the Court Documents page provides additional detail.
  - **Excluded parties:** The precise exclusion language was not reproduced on the homepage. Reviewer should pull the full Class Action Notice from the Court Documents page and update the "Who Is Excluded" section accordingly.
  - **Jazz vs. Hikma allocation:** The $195 million figure is presented as a combined total for Jazz and Hikma; the individual amounts attributable to each defendant are not disclosed on the homepage. Reviewer may wish to check Court Documents for the individual settlement agreement amounts.
- **Note on payment timing vs. article date:** As of the Last Updated date of 2026-10-28, Q4 2026 is currently underway. The source page states payments are "expected" in Q4 2026 but does not confirm they have been issued. FRS staff should monitor the settlement website for confirmation that distributions have gone out.